Clinical trials: Ovarian Cancers
Malignancy, Non-hodgkin Lymphoma
A Phase 1/2 Study of CYT-0851 in B-Cell Malignancies and Advanced Solid Tumors
This clinical trial is an interventional, active-treatment, open-label, multi-center, Phase 1/2 study. The study objectives are to assess the safety, tolerability and pharmacokinetics (PK) of CYT-0851 in patients with…
- Conditions
- Malignancy, Non-hodgkin Lymphoma, Multiple Myeloma, Breast Cancer
- Trial name
- NCT03997968
- Testing
- CYT-0851, CYT-0851 in combination with gemcitabine, CYT-0851 in combination with capecitabine
- Where
- 16 sites in United States
- Volunteers
- 169 people
- Sponsor
- Cyteir Therapeutics, Inc.
Bladder Cancer, Cervical Cancer
Hyperbaric Oxygen Therapy in Treating Long-Term Gastrointestinal Adverse Effects Caused by Radiation Therapy in Patients With Pelvic Cancer
RATIONALE: Radiation therapy can cause long-term adverse effects. Hyperbaric oxygen therapy may be effective in lessening gastrointestinal symptoms caused by radiation therapy given for pelvic cancer.
- Conditions
- Bladder Cancer, Cervical Cancer, Colorectal Cancer, Endometrial Cancer
- Trial name
- NCT01087268
- Testing
- questionnaire administration, gastrointestinal complications management/prevention, quality-of-life assessment
- Where
- United Kingdom
- Volunteers
- 75 people
- Sponsor
- Royal Marsden NHS Foundation Trust
Platinum-resistant Recurrent Ovarian Cancer
A Study of B013 in Combination With Paclitaxel in Patients With Platinum-resistant Recurrent Ovarian Cancer.
To evaluate the efficacy and safety of B013 in patients with platinum-resistant recurrent ovarian cancer.
- Trial name
- NCT06434610
- Testing
- B013, Paclitaxel
- Where
- 17 sites in China
- Volunteers
- 90 people
- Sponsor
- Shanghai Jiaolian Drug Research and Development Co., Ltd
Brenner Tumor, Fallopian Tube Cancer
Carboplatin and Paclitaxel With or Without Bevacizumab Compared to Docetaxel, Carboplatin, and Paclitaxel in Treating Patients With Stage II, Stage III, or Stage IV Ovarian Epithelial, Fallopian Tube, or Primary Peritoneal Cavity Carcinoma (Cancer)
This phase I trial is studying the side effects and best dose of intraperitoneal infusions of carboplatin when given together with intravenous infusions of either docetaxel or paclitaxel followed by intraperitoneal paclitaxel in…
- Conditions
- Brenner Tumor, Fallopian Tube Cancer, Ovarian Carcinosarcoma, Ovarian Clear Cell Cystadenocarcinoma
- Trial name
- NCT00085358
- Testing
- carboplatin, paclitaxel, docetaxel
- Where
- 16 sites in United States
- Volunteers
- 40 people
- Sponsor
- National Cancer Institute (NCI)
Ovarian Cancer, Neoadjuvant Chemotherapy
PD-1 Antibody Combined Neoadjuvant Chemotherapy for Ovarian Cancer
The main purpose of this study is to validate the efficacy and safety of anti-PD-1 in combination with neoadjuvant chemotherapy in women with advanced ovarian cancer.
- Conditions
- Ovarian Cancer, Neoadjuvant Chemotherapy, Anti-PD-1, Neoadjuvant Immunotherapy
- Trial name
- NCT04815408
- Testing
- BGB-A317, albumin-bound paclitaxel 260mg/m2 , Carboplatin AUC 5
- Where
- China
- Volunteers
- 40 people
- Sponsor
- Second Affiliated Hospital, Zhejiang University, School of Medicine
Solid Tumor, Hepatocellular Carcinoma
Intravenous T3011 Given as a Single Agent and in Combination With Other Therapy in Subjects With Advanced Solid Tumors
A Phase 1/2a Open-Label Dose Escalation and Dose Expansion Study of T3011 when Administered Intravenously as a Single Agent and in Combination with Other Therapy in Subjects with Advanced Solid Tumors
- Conditions
- Solid Tumor, Hepatocellular Carcinoma, Colorectal Cancer, NSCLC
- Trial name
- NCT04780217
- Testing
- T3011
- Where
- 6 sites in United States
- Volunteers
- 42 people
- Sponsor
- ImmVira Pharma Co. Ltd
Polycystic Ovary Syndrome
Intestinal Microbiota Survey of Polycystic Ovary Syndrome
Polycystic Ovary Syndrome is kind of disease with unclear etiology. Recent studies on intestinal microbiota have raised the possibility that dysbiosis of intestinal microbiota maybe a novel theory for the development of…
- Trial name
- NCT02937090
- Testing
- Blood Draw, Stool collection
- Where
- China
- Volunteers
- 80 people, healthy volunteers welcome
- Sponsor
- The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School
Acute Myeloid Leukemia
Minimal Residual Disease Evaluation on Cryopreserved Ovarian Fragments in Younger Patients Treated for Acute Myeloid Leukemia
Cryopreservation of ovarian cortex represents an option for fertility preservation in patients diagnosed with acute myeloid leukemia and requiring allogeneic stem cell transplantation.
- Trial name
- FERTILAM (NCT04679285)
- Where
- France
- Volunteers
- 9 people
- Sponsor
- University Hospital, Lille
Ovarian Cancer
Efficacy and Safety Study of Sorafenib With Topotecan in Patients With Platinum-resistant Recurrent Ovarian Cancer
It is assumed, that the patients of the standard arm show a median progression-free survival time of 4.4 months those of the experimental arm of at least 6.9 months.
- Trial name
- TRIAS 2009 (NCT01047891)
- Testing
- Sorafenib
- Where
- Germany
- Volunteers
- 174 people
- Sponsor
- JSehouli
PCOS (Polycystic Ovary Syndrome)
Fecal Microbiota Transplantation for Obese Women With Polyendocrine Metabolic Ovarian Syndrome
This prospective, two-stage clinical trial aims to evaluate the safety, preliminary efficacy, and reproductive outcomes of oral Fecal Microbiota Transplantation (FMT) freeze-dried capsules in overweight and obese patients with…
- Trial name
- FMT-PMOS (NCT07746635)
- Testing
- oral Fecal Microbiota Transplantation
- Where
- China
- Volunteers
- 201 people
- Sponsor
- Shanghai Changzheng Hospital
Breast Cancer, Leukemia
Phase I/II Study of Escalating-Dose Melphalan w/Autologous SCS & Amifostine Cytoprotect
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining chemotherapy with peripheral stem cell transplantation may allow the doctor to give higher doses of…
- Conditions
- Breast Cancer, Leukemia, Lymphoma, Neuroblastoma
- Trial name
- NCT00003425
- Testing
- filgrastim, amifostine trihydrate, cyclophosphamide
- Where
- 4 sites in United States
- Volunteers
- 25 people
- Sponsor
- University of Kentucky
Ovarian Carcinoma, Fallopian Tube Carcinoma
(PGA) for Platinum-resistant/Refractory, Paclitaxel-Pretreated Recurrent Ovarian and Peritoneal Carcinoma
To evaluate progression-free survival with two chemotherapy regimens on platinum-resistant/refractory ovarian and peritoneal carcinoma
- Conditions
- Ovarian Carcinoma, Fallopian Tube Carcinoma, Peritoneal Carcinoma
- Trial name
- PGA (NCT01936974)
- Testing
- Gemcitabine, Bevacizumab, Carboplatin
- Where
- United States
- Volunteers
- 7 people
- Sponsor
- Western Regional Medical Center
Mesothelin-Expressing Tumors, Epithelial Ovarian Cancer
CT-95 in Advanced Cancers Associated With Mesothelin Expression
This is a Phase 1a/1b, first-in-human (FIH), open-label, multi-center dose escalation and expansion study of the safety, pharmacokinetics (PK), pharmacodynamics, and antitumor activity of single-agent CT-95 in subjects with…
- Conditions
- Mesothelin-Expressing Tumors, Epithelial Ovarian Cancer, Malignant Pleural Mesothelioma, Advanced, Malignant Peritoneal Mesothelioma, Advanced
- Trial name
- NCT06756035
- Testing
- CT-95
- Where
- 9 sites in United States
- Volunteers
- 70 people
- Sponsor
- Context Therapeutics Inc.
Epithelial Ovarian Cancer
Phase I/II Study of Pazopanib and Cyclophosphamide in Patients With Platinum-resistant Recurrent Ovarian Cancer
The current trial shall clarify the potential of the multitarget antiangiogenic tyrosinkinase inhibitor GW 786034 (pazopanib) in combination with oral cyclophosphamide as salvage treatment in patients with recurrent, pretreated…
- Trial name
- NCT01238770
- Testing
- Pazopanib
- Where
- 5 sites in Germany
- Volunteers
- 10 people
- Sponsor
- Priv.-Doz. Dr. med. Joachim Rom
Esophageal Cancer, Lung Cancer
Safety and Immunogenicity of CHP-HER2 and CHP-NY-ESO-1 Protein With OK-432 in Antigen-Expressing Cancers
Mixed cancer vaccines, CHP-HER2 protein and CHP-NY-ESO-1 protein, are to be studied to evaluate the safety and immune responses in patients who are positive either or both antigens.
- Conditions
- Esophageal Cancer, Lung Cancer, Stomach Cancer, Breast Cancer
- Trial name
- NCT00291473
- Testing
- CHP-HER2, CHP-NY-ESO-1
- Where
- Japan
- Volunteers
- 9 people
- Sponsor
- Ludwig Institute for Cancer Research
Ovarian Cancer
IM-862 in Treating Patients With Recurrent Ovarian Cancer
RATIONALE: IM-862 may stop the growth of ovarian cancer by stopping blood flow to the tumor. PURPOSE: Phase I trial to study the effectiveness of IM-862 in treating patients who have recurrent ovarian cancer after treatment with…
- Trial name
- NCT00003773
- Testing
- oglufanide disodium
- Where
- United States
- Volunteers
- 43 people
- Sponsor
- University of Southern California
Solid Tumor, Advanced Solid Tumor
A Study on the Prevalence of Clinically Useful Mutations in Solid Tumor Characterized by Next Generation Sequencing Methods on Liquid Biopsy Analysis (POPCORN)
The implementation of liquid biopsy in clinical practice has been favored by the rapid development of genome sequencing techniques designed to analyze mutations in ctDNA.
- Conditions
- Solid Tumor, Advanced Solid Tumor, Locally Advanced Solid Tumor, Colon Rectal Cancer
- Trial name
- POPCORN (NCT06028724)
- Where
- Italy
- Volunteers
- 782 people
- Sponsor
- Centro di Riferimento Oncologico - Aviano
Ovary Cancer
The Efficacy and Safety of FRD001 in Ultrasound Contrast Imaging for Malignant Ovarian Masses in Women
This is a Prospective, Self-Controlled, Open-Label, Multicenter Clinical Trial. The purpose of this study is to demonstrate the efficacy and safety of FRD001 injection in ultrasound contrast imaging for the differentiation…
- Trial name
- NCT06556342
- Testing
- FRD001
- Where
- China
- Volunteers
- 198 people
- Sponsor
- Tongji Hospital
Solid Tumors, Ovarian Cancer
A Phase I Dose-escalation Study of Subcutaneous ALM201 in Patients With Advanced Ovarian Cancer and Other Solid Tumours
ALM201/0001 is a Phase I, open-label, dose-escalation study of the safety, tolerability and pharmacokinetics (PK) of ALM201. Part 1 will be a dose-escalation study.
- Trial name
- NCT03427073
- Testing
- ALM201
- Where
- 3 sites in United Kingdom
- Volunteers
- 20 people
- Sponsor
- Almac Discovery
PI3K Pathway Activated Tumors
BKM120 for Patients With PI3K-activated Tumors
The purpose of this signal seeking study was is to determine whether treatment with BKM120 demonstrates sufficient efficacy in select pathway-activated solid tumors and/or hematologic malignancies to warrant further study.
- Trial name
- SIGNATURE (NCT01833169)
- Testing
- BKM120
- Where
- 59 sites in United States
- Volunteers
- 146 people
- Sponsor
- Novartis Pharmaceuticals
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.